Abstract
Worldwide infectious disease is one of the leading causes of death. Despite improvements in technology and healthcare services, morbidity and mortality due to infections have remained unchanged over the past few decades. The high and increasing rate of antibiotic resistance is further aggravating the situation. Growing resistance hampers the use of conventional antibiotics, and substantial higher mortality rates are reported in patients given ineffective empiric therapy mainly due to resistance to the agents used. These infections cause suffering, incapacity, and death and impose an enormous financial burden on both healthcare systems and on society in general. The accelerating development of multidrug resistance is one of the greatest diagnostic and therapeutic challenges to modern medicine. The lack of new antibiotic options underscores the need for optimization of current diagnostics, therapies, and prevention of the spread of multidrug-resistant organisms. The so-called -omics technologies (genomics, transcriptomics, proteomics, and metabolomics) have yielded large-scale datasets that advanced the search for biomarkers of infectious diseases in the last decade. One can imagine that in the future the implementation of biomarker-driven molecular test systems will transform diagnostics of infectious diseases and will significantly accelerate the identification of the bacterial pathogens at the infected host site. Furthermore, molecular tests based on the identification of markers of antibiotic resistance will dramatically change resistance profiling. The replacement of culturing methods by molecular test systems for early diagnosis will provide the basis not only for a prompt and targeted therapy, but also for a much more effective stewardship of antibiotic agents and a reduction of the spread of multidrug resistance as well as the appearance of new antibiotic resistances.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
Ackermann BL, Hale JE, Duffin KL (2006) The role of mass spectrometry in biomarker discovery and measurement. Curr Drug Metab 5:525–539
Arnold C, Westland L, Mowat G et al (2005) Single-nucleotide polymorphism-based differentiation and drug resistance detection in Mycobacterium tuberculosis from isolates or directly from sputum. Clin Microbiol Infect 11:122–130
Balding DJ (2006) A tutorial on statistical methods for population association studies. Nat Rev Genet 7:781–791
Banoei MM, Donnelly SJ, Mickiewicz B et al (2014) Metabolomics in critical care medicine: a new approach to biomarker discovery. Clin Invest Med 37:E363–E376
Biomarkers Definitions Working Group (2001) Biomarkers and surrogate endpoints: preferred definitions and conceptual framework. Clin Pharmacol Ther 69:89–95
Cai HY, Caswell JL, Prescott JF (2014) Nonculture molecular techniques for diagnosis of bacterial disease in animals: a diagnostic laboratory perspective. Vet Pathol 51:341–350
Call DR, Bakko MK, Krug MJ et al (2003) Identifying antimicrobial resistance genes with DNA microarrays. Antimicrob Agents Chemother 47:3290–3295
Cegelski L, Marshall GR, Eldridge GR et al (2008) The biology and future prospects of antivirulence therapies. Nat Rev Microbiol 6:17–27
Chen PE, Shapiro BJ (2015) The advent of genome-wide association studies for bacteria. Curr Opin Microbiol 25:17–24
Classen S, Staratschek-Jox A, Schultze JL (2008) Use of genome-wide high-throughput technologies in biomarker development. Biomark Med 2:509–524
Collino S, Martin FP, Rezzi S (2013) Clinical metabolomics paves the way towards future healthcare strategies. Br J Clin Pharmacol 75:619–629
Croxatto A, Prod’hom G, Greub G (2012) Applications of MALDI-TOF mass spectrometry in clinical diagnostic microbiology. FEMS Microbiol Rev 36:380–407
Dellinger RP, Levy MM, Rhodes A et al, Surviving Sepsis Campaign Guidelines Committee including the Pediatric Subgroup (2012) Surviving sepsis campaign: international guidelines for management of severe sepsis and septic shock: 2012. Crit Care Med 41:580–637
Didelot X, Bowden R, Wilson DJ et al (2012) Transforming clinical microbiology with bacterial genome sequencing. Nat Rev Genet 13:601–612
Dittmar G, Selbach M (2015) SILAC for biomarker discovery. Proteomics Clin Appl 9:301–306
Dunne WM Jr, Westblade LF, Ford B (2012) Next-generation and whole-genome sequencing in the diagnostic clinical microbiology laboratory. Eur J Clin Microbiol Infect Dis 31:1719–1726
Endimiani A, Hujer KM, Hujer AM et al (2011) Are we ready for novel detection methods to treat respiratory pathogens in hospital-acquired pneumonia? Clin Infect Dis 52(Suppl 4):S373–S383
European Commission (2010) Biomarkers for patient stratification. http://ec.europa.eu/research/health/pdf/biomarkers-for-patient-stratification_en.pdf
Farhat MR, Shapiro BJ, Kieser KJ et al (2013) Genomic analysis identifies targets of convergent positive selection in drug-resistant Mycobacterium tuberculosis. Nat Genet 45:1183–1189
Fitousis K, Moore LJ, Hall J et al (2010) Evaluation of empiric antibiotic use in surgical sepsis. Am J Surg 200:776–782
Francis RO, Wu F, Della-Latta P et al (2012) Rapid detection of Klebsiella pneumoniae carbapenemase genes in enterobacteriaceae directly from blood culture bottles by real-time PCR. Am J Clin Pathol 137:627–632
Garnacho-Montero J, Garcia-Garmendia JL, Barrero-Almodovar A et al (2003) Impact of adequate empirical antibiotic therapy on the outcome of patients admitted to the intensive care unit with sepsis. Crit Care Med 31:2742–2751
He QY, Chiu JF (2003) Proteomics in biomarker discovery and drug development. J Cell Biochem 89:868–886
Hrabák J, Walková R, Studentová V et al (2011) Carbapenemase activity detection by matrix-assisted laser desorption ionization-time of flight mass spectrometry. J Clin Microbiol 49:3222–3227
Infectious Diseases Society of America (2011) An unmet medical need: rapid molecular diagnostics tests for respiratory tract infections. Clin Infect Dis 52(Suppl 4):S384–S395
Kilianski A, Haas JL, Corriveau EJ et al (2015) Bacterial and viral identification and differentiation by amplicon sequencing on the MinION nanopore sequencer. Gigascience 4:12
Köser CU, Ellington MJ, Cartwright EJ et al (2012) Routine use of microbial whole genome sequencing in diagnostic and public health microbiology. PLoS Pathog 8:e1002824
Kostrzewa M, Sparbier K, Maier T et al (2013) MALDI-TOF MS: an upcoming tool for rapid detection of antibiotic resistance in microorganisms. Proteomics Clin Appl 7:767–778
Kumar A, Roberts D, Wood KE et al (2006) Duration of hypotension before initiation of effective antimicrobial therapy is the critical determinant of survival in human septic shock. Crit Care Med 34:1589–1596
Lawn SD, Mwaba P, Bates M et al (2013) Advances in tuberculosis diagnostics: the Xpert MTB/RIF assay and future prospects for a point-of-care test. Lancet Infect Dis 13:349–361
Leekitcharoenphon P, Nielsen EM, Kaas RS et al (2014) Evaluation of whole genome sequencing for outbreak detection of Salmonella enterica. PLoS ONE 9:e87991
Liotta LA, Ferrari M, Petricoin E (2003) Clinical proteomics: written in blood. Nature 425:905
Livermore DM, Wain J (2013) Revolutionising bacteriology to improve treatment outcomes and antibiotic stewardship. Infect Chemother 45:1–10
MacArthur RD, Miller M, Albertson T et al (2004) Adequacy of early empiric antibiotic treatment and survival in severe sepsis: experience from the MONARCS trial. Clin Infect Dis 38:284–288
Maiden MC, Bygraves JA, Feil E et al (1998) Multilocus sequence typing: a portable approach to the identification of clones within populations of pathogenic microorganisms. Proc Natl Acad Sci USA 95:3140–3145
Mardis ER (2008) Next-generation DNA sequencing methods. Annu Rev Genomics Hum Genet 9:387–402
Mardis ER (2013) Next-generation sequencing platforms. Annu Rev Anal Chem 6:287–303
Myers FB, Henrikson RH, Xu L et al (2011) A point-of-care instrument for rapid multiplexed pathogen genotyping. Conf Proc IEEE Eng Med Biol Soc 2011:3668–3671
Pai NP, Vadnais C, Denkinger C et al (2012) Point-of-care testing for infectious diseases: diversity, complexity, and barriers in low- and middle-income countries. PLoS Med 9:e1001306
Pritchard JK, Donnelly P (2001) Case-control studies of association in structured or admixed populations. Theor Popul Biol 60:227–237
Rai AJ (2007) Biomarkers in translational research: focus on discovery, development and translation of protein biomarkers to clinical immunoassays. Expert Rev Mol Diagn 7:545–553
Randell P (2014) It’s a MALDI but it’s a goodie: MALDI-TOF mass spectrometry for microbial identification. Thorax 69:776–778
Read TD, Massey RC (2014) Characterizing the genetic basis of bacterial phenotypes using genome-wide association studies: a new direction for bacteriology. Genome Med 6:109
Reinhart K, Hartog CS (2010) Biomarkers as a guide for antimicrobial therapy. Int J Antimicrob Agents 36:S17–S21
Rodrigues Ribeiro Teles FS, de Távora Pires, Tavira LA, Pina da Fonseca LJ (2010) Biosensors as rapid diagnostic tests for tropical diseases. Crit Rev Clin Lab Sci 47:139–169
Schürch AC, Siezen RJ (2010) Genomic tracing of epidemics and disease outbreaks. Microb Biotechnol 3:628–633
Soo Hoo GW, Wen YE, Nguyen TV et al (2005) Impact of clinical guidelines in the management of severe hospital-acquired pneumonia. Chest 128:2778–2787
Sparbier K, Schubert S, Weller U et al (2012) Matrix-assisted laser desorption ionization-time of flight mass spectrometry-based functional assay for rapid detection of resistance against β-lactam antibiotics. J Clin Microbiol 50:927–937
Strauss C, Endimiani A, Perreten V (2014) A novel universal DNA labeling and amplification system for rapid microarray-based detection of 117 antibiotic resistance genes in Gram-positive bacteria. J Microbiol Methods 108:25–30
van Belkum A (2003) Molecular diagnostics in medical microbiology: yesterday, today and tomorrow. Curr Opin Pharmacol 3:497–501
van Dijk EL, Auger H, Jaszczyszyn Y et al (2014) Ten years of next-generation sequencing technology. Trends Genet 30:418–426
Wallis RS, Pai M, Menzies D et al (2010) Biomarkers and diagnostics for tuberculosis: progress, needs, and translation into practice. Lancet 375:1920–1937
World Health Organization (2004) Mapping the landscape of diagnostics for sexually transmitted infections. http://www.who.int/tdr/publications/documents/mapping-landscape-sti.pdf
Zhao YY, Cheng XL, Lin RC et al (2015) Lipidomics applications for disease biomarker discovery in mammal models. Biomark Med 9:153–168
Zignol M, van Gemert W, Falzon D et al (2012) Surveillance of anti-tuberculosis drug resistance in the world: an updated analysis, 2007–2010. Bull World Health Organ 90:111–119D
Zolg JW, Langen H (2004) How industry is approaching the search for new diagnostic markers and biomarkers. Mol Cell Proteomics 3:345–354
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2016 Springer International Publishing AG
About this chapter
Cite this chapter
Hornischer, K., Häußler, S. (2016). Diagnostics and Resistance Profiling of Bacterial Pathogens. In: Stadler, M., Dersch, P. (eds) How to Overcome the Antibiotic Crisis . Current Topics in Microbiology and Immunology, vol 398. Springer, Cham. https://doi.org/10.1007/82_2016_494
Download citation
DOI: https://doi.org/10.1007/82_2016_494
Published:
Publisher Name: Springer, Cham
Print ISBN: 978-3-319-49282-7
Online ISBN: 978-3-319-49284-1
eBook Packages: Biomedical and Life SciencesBiomedical and Life Sciences (R0)